Neurocrine Biosciences (NBIX) Aandelenoverzicht
Neurocrine Biosciences, Inc. ontdekt, ontwikkelt en verkoopt geneesmiddelen voor neurologische, psychiatrische, endocriene en immunologische aandoeningen in de Verenigde Staten en daarbuiten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor NBIX uit onze risicocontroles.
NBIX Community Fair Values
Create NarrativeSee what 84 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$244.8
FV
34.0% ondergewaardeerd intrinsieke korting17.00%
Revenue growth p.a.
1.3k
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
Neurocrine Biosciences, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$161.62 |
| 52 Week Hoogtepunt | US$169.57 |
| 52 Week Laag | US$122.14 |
| Bèta | 0.40 |
| 1 maand verandering | 3.14% |
| 3 maanden verandering | 23.25% |
| 1 Jaar Verandering | 26.09% |
| 3 jaar verandering | 70.68% |
| 5 jaar verandering | 66.72% |
| Verandering sinds IPO | 1,192.96% |
Recent nieuws en updates
Analyseartikel • Jun 19
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults. See our latest analysis for Neurocrine Biosciences. At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026...
Narratiefupdate • Jun 09
NBIX: Future Upside Will Depend On Rare Disease Portfolio Execution
Analysts have lifted the fair value estimate for Neurocrine Biosciences by about $6 to $192.88, reflecting updated views on revenue growth, profitability and valuation after the Soleno acquisition, along with recent Street research highlighting a long runway for key drugs and additional contributions from Vykat XR. Analyst Commentary Recent Street research around Neurocrine Biosciences has been broadly constructive, with several firms updating models after the Soleno acquisition and new readthroughs on key products.Recent updates
Analyseartikel • Jun 19
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults. See our latest analysis for Neurocrine Biosciences. At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026...Narratiefupdate • Jun 09
NBIX: Future Upside Will Depend On Rare Disease Portfolio Execution
Analysts have lifted the fair value estimate for Neurocrine Biosciences by about $6 to $192.88, reflecting updated views on revenue growth, profitability and valuation after the Soleno acquisition, along with recent Street research highlighting a long runway for key drugs and additional contributions from Vykat XR. Analyst Commentary Recent Street research around Neurocrine Biosciences has been broadly constructive, with several firms updating models after the Soleno acquisition and new readthroughs on key products.
Narratiefupdate • May 26
NBIX: Pipeline Execution And Integration Risks Will Shape Balanced Future Returns
Analysts lifted their fair value target for Neurocrine Biosciences by about $3 to $144, citing updated assumptions for revenue growth of 14.83%, a profit margin of 18.43%, and a recalibrated future P/E of 21.28x that reflects confidence in the long runway of its key approved drugs and potential contributions from Crenessity and osavampator. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a mix of optimism around the company’s approved therapies and emerging pipeline, alongside selective caution on execution and valuation.Analyseartikel • May 08
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next
Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...
Narratiefupdate • May 07
NBIX: Future Upside Will Depend On Execution Across Two Core Franchises
The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.Seeking Alpha • May 06
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside
Summary Neurocrine Biosciences delivered a strong Q1, with revenue up 42% and healthy growth in Ingrezza and Crenessity. Enhanced sales efforts could drive Ingrezza upside in 2H'26, while Crenessity has a long runway for patient adoption, particularly in adults. The $2.9 billion Soleno acquisition brings Vykat XR, a high-potential offering with clear commercial synergies but significant unknowns around long-term patient uptake and compliance. My fair value estimate for NBIX rises to just under $206/share, supported by multiyear upside in Ingrezza, Crenessity, and a promising, though long-dated, pipeline. I maintain a bullish stance on NBIX, seeing the market undervaluing core franchises and risk-adjusted pipeline upside despite tempered guidance. Read the full article on Seeking AlphaNarratiefupdate • Apr 21
NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution
The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.Narratiefupdate • Apr 07
NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns
Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.Narratiefupdate • Mar 24
NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress
Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.Narratiefupdate • Mar 09
NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns
Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.Narratiefupdate • Feb 23
NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook
Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.Narratiefupdate • Feb 09
NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery
Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.Narratiefupdate • Jan 24
NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises
Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.Narratiefupdate • Jan 10
NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns
Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.Narratiefupdate • Dec 17
NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns
Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.Narratiefupdate • Dec 03
NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value
Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.Narratiefupdate • Nov 19
NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds
Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.Narratiefupdate • Nov 05
NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value
The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.Narratiefupdate • Oct 22
Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results
Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.Seeking Alpha • Apr 22
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Summary Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phase 3 data for valbenazine in treating dyskinetic cerebral palsy in 2025, presenting another market opportunity. Neurocrine's financial health is robust, with $1.8 billion in cash and strong revenue growth from INGREZZA, which saw a 23% year-over-year increase in Q4 2024. The Schizophrenia market across the 7 major markets is expected to reach $17 billion by 2031. Read the full article on Seeking AlphaSeeking Alpha • Apr 16
Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity
Summary Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling product. Despite a recent sell-off due to missed earnings targets and cautious 2025 guidance, Neurocrine's pipeline, including the newly approved Crenessity, may offer substantial growth potential. The company's robust portfolio and promising pipeline, including potential blockbusters like Crenessity and Ingrezza (valbenazine) label expansions, make it an intriguing contrarian buy opportunity. NBIX stock's valuation compared to peers suggests the recent market reaction may be overdone, positioning it as a potential takeover target with a valuation closer to $15 billion, in my view. Read the full article on Seeking AlphaRendement voor aandeelhouders
| NBIX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 3.3% | 2.8% | -1.8% |
| 1Y | 26.1% | 35.2% | 23.3% |
Rendement versus industrie: NBIX presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 35.2 % opleverde.
Rendement versus markt: NBIX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 23.3 %.
Prijsvolatiliteit
| NBIX volatility | |
|---|---|
| NBIX Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: NBIX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van NBIX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1992 | 2,000 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. ontdekt, ontwikkelt en verkoopt geneesmiddelen voor neurologische, psychiatrische, endocriene en immunologische aandoeningen in de Verenigde Staten en daarbuiten. De producten van het bedrijf omvatten INGREZZA voor tardieve dyskinesie en chorea die geassocieerd worden met de ziekte van Huntington; Orilissa-tabletten voor endometriose; Oriahnn-capsules voor de behandeling van baarmoederfibromen; en CRENESSITY voor de behandeling van congenitale bijnierhyperplasie, en biedt daarnaast producten aan onder de naam ALKINDI en Efmody. De productkandidaten in klinische ontwikkeling omvatten NBI-1076986 voor de behandeling van bewegingsstoornissen; Osavampator voor onvoldoende respons op behandeling bij depressieve stoornissen; NBI-1117568 voor de behandeling van schizofrenie en bipolaire manie; NBI-1117567 voor de behandeling van de ziekte van Alzheimer; NBI 921355 voor de behandeling van epilepsie; NBIP-01435 voor de behandeling van congenitale bijnierhyperplasie; NBIP-2118 voor de behandeling van obesitas en verwante metabolische ziekten; en NBI-1070770 voor de behandeling van depressieve stoornissen; en NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675 en NBI-1065890 voor neuropsychiatrische en neurologische aandoeningen.
Neurocrine Biosciences, Inc. Samenvatting
| NBIX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$16.25b |
| Inkomsten(TTM) | US$668.60m |
| Inkomsten(TTM) | US$3.10b |
24.3x
Koers/Winstverhouding5.2x
P/S-verhoudingIs NBIX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| NBIX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$3.10b |
| Kosten van inkomsten | US$1.11b |
| Brutowinst | US$2.00b |
| Overige uitgaven | US$1.33b |
| Inkomsten | US$668.60m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 6.65 |
| Brutomarge | 64.37% |
| Nettowinstmarge | 21.55% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde NBIX op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/23 18:52 |
| Aandelenkoers aan het einde van de dag | 2026/06/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Neurocrine Biosciences, Inc. wordt gevolgd door 39 analisten. 21 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Aydin Huseynov | Benchmark Company |